Genentech Discloses Promising Data on Perjeta in Neoadjuvant Treatment For Specific Breast Cancer Patients

Genentech Discloses Promising Data on Perjeta in Neoadjuvant Treatment For Specific Breast Cancer Patients
Genentech, a member of the Roche Group, recently announced encouraging results on its Phase II NeoSphere trial evaluating Perjeta (pertuzumab) as a neoadjuvant (pre-surgery) treatment in specific early breast cancer patients. The data was presented by Dr. Luca Gianni from San Raffaele Hospital, Scientific Institute, Italy (Abstract #505) on May 31 during the 2015 American Society of

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *